Streetbeat News

Revenues

TGNA

TEGNA Inc. expects a mid-to-high teens percent decrease in Q4 2023 revenue due to the absence of $179M of high-margin political revenue reported in Q4 2022. The company's total non-GAAP operating expenses are projected to increase by a low-single digit percent, while non-GAAP operating expenses excluding programming are expected to decrease by a low-single digit percent.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 1:05 pm

OESX

Orion Energy Systems (OESX) expects FY 2024 revenue growth of 30% or more to approximately $100M, with most of the increase occurring in the second half of the year. The company's EV is anticipated to strengthen in 2H FY24 due to increased project activation and equipment sales through partners. LED lighting growth is also expected in 2H FY'24 from a range of large national account projects currently underway or anticipated over the balance of the fiscal year.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 1:00 pm

ML

MoneyLion has projected its FY23 revenues to be between $420M-$425M, which is lower than the estimated $429.17M. The company also expects its FY23 adjusted EBITDA to be between $39M-$45M and sees a gross profit margin of 58%-59%.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 12:43 pm

MSGE

Madison Square Garden Entertainment (MSGE) has reaffirmed its previously issued FY24 guidance for revenues of $900M-$930M.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 12:42 pm

BOWL

Bowlero Corp has reiterated its FY24 revenue guidance of $1.14B - $1.19B, which is in line with the estimated $1.16B. The company also expects Q2 revenue to be between $295M-$310M, compared to the estimated $299.71M. The company plans to heavily reinvest in the business in FY24, with over $160M allocated to acquisitions, $40M to new builds, and $75M to conversions.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 12:40 pm

HBIO

Harvard Bioscience has revised its FY23 revenue forecast to be approximately flat compared to 2022, due to headwinds in Asia. This is a change from its earlier expectation of $116M-$120M, and is below the consensus estimate of $116.95M.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 12:38 pm

STIM

Neuronetics has projected its Q4 FY23 revenues to be between $19M and $21M, which is in line with the consensus estimate of $19.76M.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 12:35 pm

IMXI

International Money Express (IMXI) anticipates Q4 revenue to be between $170.0M and $181.0M, compared to the consensus estimate of $174.13M.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 12:34 pm

STIM

Neuronetics has updated its FY23 revenue guidance to $70M-$72M, a slight adjustment from the previous range of $69M-$73M. The new guidance is in line with the consensus estimate of $70.50M.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 12:33 pm

SGRY

Surgery Partners has projected its FY23 revenue to be $2.75 billion, slightly below the estimated $2.76 billion.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 12:33 pm